Prime Medicine, Inc.
$2.88
The Read: Prime Medicine’s stock fell nearly 15% after Q4 2025 earnings due to a revenue miss and high burn rate despite stronger cash than expected, then declined slightly by 1.4% when no strategic financing or partnership funding materialized.
Price
Overlays
Panel
PRME
Hover to view data
No Data